[Nitric oxide donor increases the effectiveness of cytostatic therapy and inhibits the development of drug resistance].
The investigation has established a potential of low-dosage chemotherapy with cytostatics when used in combination with nitric oxide (NO) donor. Such regimen resulted in more animals being cured of leukemias P388 and L1210 and longer survival. Similar effect was reported with transplantable intracerebral leukemia P388 in which case mean survival after cyclophosphamide plus NO-donor was three times as high as that after cyclophosphamide alone. Combination therapy also promoted animetastatic effect: melanoma B16 inhibition by cyclophosphamide alone was 50% vs. 80% after cyclophosphamide plus NO-donor. NO-donor inhibited development of drug resistance to cyclophosphamide.
Konovalova
N P
NP
Institute of Problems of Chemical Physics, Russian Academy of Sciences, Chernogolovka.
Goncharova
S A
SA
Volkova
L M
LM
Raevskaia
T A
TA
Eremenko
L T
LT
Korolev
A M
AM
D000008:Abdominal Neoplasms / Q000188:drug therapy; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000494:pharmacology*; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007941:Leukemia P388 / Q000188:drug therapy*; D008546:Melanoma, Experimental / Q000188:drug therapy*; D009368:Neoplasm Transplantation; D020030:Nitric Oxide Donors / Q000494:pharmacology*
D018906:Antineoplastic Agents, Alkylating; D020030:Nitric Oxide Donors; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin
Donor oksida azota povyshaet éffektivnost' tsitostaticheskoĭ terapii i zaderzhivaet razvitie lekarstvennoĭ rezistentnosti.